| Abstract | 28 patients with Parkinson's disease and long-term levodopa therapy have received additional selegiline (10 mg/d) over the past 3 years and been followed up for a mean period of 18.8 months. Two thirds improved with a reduction of global disability and amelioration of end-of-dose effects, nocturnal and early-morning akinesia. Peak-dose dyskinesias tended to increase with selegiline while biphase and off-period involuntary movements improved in some cases. Patients already on maximally tolerated doses of levodopa and those with severe on-off swings did not gain significant benefit. 8 of 18 responders lost their initial response within 1.5 years. |
| Authors | W Poewe, F Gerstenbrand, G Ransmayr
(Affiliation: University Clinic of Neurology, Innsbruck, Austria.)
|
| Journal | Journal of neural transmission. Supplementum
(J Neural Transm Suppl)
Vol. 25
Pg. 131-5
( 1987)
ISSN: 0303-6995 AUSTRIA |
| PMID | 3123599
(Publication Type: Journal Article)
|
| Chemical References |
- Phenethylamines
- Selegiline
|
| Topics |
- Disability Evaluation
- Humans
- Parkinson Disease
(drug therapy, physiopathology)
- Phenethylamines
(therapeutic use)
- Retrospective Studies
- Selegiline
(therapeutic use)
- Time Factors
|
